$IBRX INSIGHTS →ImmunityBio ~700% revenue growth in 2025 was driven by strong uptake of cancer therapy Anktiva
Read the full research in the app
A subscription is required to access the full thread.
Open in the app →$IBRX INSIGHTS →$IBRX INSIGHTS →